- Beamtree Holdings (BMT) partners with global healthcare company Abbott to distribute its RippleDown AI products
- The company says the three-year contract marks a step forward and joint approach to advancing automation through its core diagnostics product
- Abbott will distribute RippleDown, rebranded as AlinIQ Clinical Decision Support Powered by RippleDown, in pathology and radiology clinics
- Abbott will retain exclusive distribution rights, except for a single existing distribution agreement
- Beamtree Holdings is up 11.3 per cent, trading at 34.5 cents at 12.26pm AEDT
Beamtree Holdings (BMT) has penned a new agreement with global healthcare company, Abbott to distribute its RippleDown products.
The company said the three-year agreement marked a step forward to advancing automation and value through its core diagnostics product.
The company’s RippleDown product automates expert decision making in clinical and administrative processes in pathology, automatically applying clinical expertise to generate patient-centric reports.
Beamtree CEO Tim Kelsey said he was delighted to announce the expansive opportunity for Beamtree, which he believed further solidifies the company’s international growth and ambition.
“Beamtree is a pioneer in the automation of human expertise, and this new partnership approach will enable us to bring RippleDown’s industry-leading technology to an expanded global market.”
Abbott will distribute RippleDown, rebranded as AlinIQ Clinical Decision Support Powered by RippleDown, in pathology and radiology clinics.
For any sales during the contractual period, Beamtree will commit to providing the RippleDown product for the duration of the end customer contract.
Abbott will retain exclusive distribution rights, except for a single existing distribution agreement.
Beamtree Holdings was up 11.3 per cent, trading at 34.5 cents at 12:26 pm AEDT.